Patents Examined by Jeffrey S. Parkin
  • Patent number: 8293465
    Abstract: The present invention relates to an antibody mimetic of carbohydrate binding module (CBM) which specifically binds to an epitope on HIV glycoprotein. The present invention also relates to a method of detecting HIV glycoprotein.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: October 23, 2012
    Assignee: National Tsing Hua University
    Inventors: Margaret Dah-Tsyr Chang, Yuan-Chuan Lee, Rong-Yuan Huang, Shu-Chuan Lin, Wei-I Chou, Shi-Hwei Liu
  • Patent number: 8287881
    Abstract: The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes.
    Type: Grant
    Filed: May 29, 2007
    Date of Patent: October 16, 2012
    Assignee: GENEART AG
    Inventors: Ralf Wagner, Markus Graf, Ludwig Deml, Kurt Bieler
  • Patent number: 8282937
    Abstract: The cold-adapted master strain A/Ann Arbor/6/60 7PI (H2N2) and progenitor wild type E2(3) viral strains have been deposited and their genomic sequences identified. Seven nucleotide differences were found between the sequences identified herein and the previously published sequences for cold-adapted A/Ann Arbor/6/60 genes. The cold-adapted live influenza virus of the present invention can be reasserted with a variety of epidemic wild type influenza viruses and used to produce vaccines to prophylactically and therapeutically treat influenza.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: October 9, 2012
    Assignee: The Regents of the University of Michigan
    Inventors: Hunein Maassab, Martha Louise Herlocher
  • Patent number: 8282926
    Abstract: The present invention relates, e.g., to an isolated peptide comprising a sequence of contiguous amino acids that is at least about 60% identical (e.g., at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 100% identical) to the sequence E-W-Q-K-E-G-L-V-T-L-W-L (SEQ ID NO:1), or an active variant of an isolated peptide comprising SEQ ID NO:1. Neutralizing antibodies generated by, or specific for, such peptides are also described, in particular antibodies which are specific for the HIV co-receptor, CCR5, and which inhibit infection of a host cell by HIV. Neutralizing single strand and complete human monoclonal antibodies against CCR5 are described. Methods of using such peptides or antibodies, for inhibiting infection by HIV, are also described.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: October 9, 2012
    Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Hana Golding, Surender Khurana
  • Patent number: 8282938
    Abstract: The present invention provides an avian influenza vaccine containing a peptide-bound liposome wherein; the peptide contains: (1) an amino acid sequence shown by any one of SEQ ID NO:1 to 9, or (2) an amino acid sequence shown by any one of SEQ ID NO:1 to 9 wherein one or two amino acids are substituted, has a length of 9 to 11 amino acids, and is capable of inducing HLA-restricted cytotoxic T lymphocytes; wherein the liposome contains a phospholipid having an acyl group with 14 to 24 carbon atoms and one unsaturated bond or a hydrocarbon group with 14 to 24 carbon atoms and one unsaturated bond, and a liposome stabilizer; and wherein the peptide is bound to the surface of the liposome.
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: October 9, 2012
    Assignees: National Institute of Infectious Diseases, National University Corporation Hokkaido University, Saitama Medical University, NOF Corporation
    Inventors: Tetsuya Uchida, Maiko Taneichi, Kiichi Kajino, Masanori Matsui, Hiroshi Oda
  • Patent number: 8232379
    Abstract: The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: July 31, 2012
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventor: Gwong-Jen J. Chang
  • Patent number: 8226955
    Abstract: Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Method of diagnosis, treatment and prevention using the polypeptides are also provided.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: July 24, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Susan W Barnett, Indresh K Srivastava
  • Patent number: 8227586
    Abstract: Provided herein is a novel human polyomavirus, its nucleic acid sequence, as well as methods to detect and diagnosis the presence of the polyomavirus.
    Type: Grant
    Filed: February 11, 2008
    Date of Patent: July 24, 2012
    Assignees: Washington University, Queensland Health
    Inventors: David Wang, Guang Wu, Anne Gaynor, Michael Nissen, Theo Sloots
  • Patent number: 8221768
    Abstract: The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus or of a chimeric immunogenic flavivirus antigen comprising sequence from more than one flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: July 17, 2012
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventor: Gwong-Jen J. Chang
  • Patent number: 8206720
    Abstract: Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.
    Type: Grant
    Filed: June 8, 2005
    Date of Patent: June 26, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Vega Masignani, Maria Scarselli, Barbara Capecchi, Victoria Sharma, Susan W. Barnett, Indresh K. Srivastava, Rino Rappuoli
  • Patent number: 8202688
    Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.
    Type: Grant
    Filed: November 20, 2002
    Date of Patent: June 19, 2012
    Assignees: University of Iowa Research Foundation, Coley Pharmaceutical GmbH, Ottawa Health Research Institute
    Inventors: Heather L. Davis, Joachim Schorr, Arthur M. Krieg
  • Patent number: 8197822
    Abstract: The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives.
    Type: Grant
    Filed: August 15, 2011
    Date of Patent: June 12, 2012
    Assignee: Bavarian Nordic A/S
    Inventors: Paul Howley, Sonja Leyrer, Paul Chaplin, Eva Felder
  • Patent number: 8197821
    Abstract: The present invention relates to protein-protein interactions involved in AIDS. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, Selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs for agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.
    Type: Grant
    Filed: February 25, 2008
    Date of Patent: June 12, 2012
    Assignee: Laboratoire Biodim
    Inventors: Pierre Legrain, Jean-Christophe Rain, Richard Benarous, Stéphane Emiliani, Clarissa Berlioz-torrent, Guillaume Blot
  • Patent number: 8197820
    Abstract: The present invention refers to Tat as the active principle for a prophylactic and/or therapeutic vaccine against HIV infection, the progression towards AIDS and the development of tumors and other syndromes and symptoms in subjects infected by HIV. Tat is in biologically active form either as recombinant protein or peptide or as DNA. More particularly, the invention refers to a vaccine based on HIV-1 Tat as immunogen, inoculated as DNA and/or recombinant protein or as peptides, alone or in combination with other genes or viral gene products (Nef, Rev, Gag) or parts thereof, or in combination with various immuno-modulant cytokines (IL-12, IL-15) or with the gene coding for an immuno-modulant cytokine or part thereof. Tat, Nef, Rev, Gag and the immuno-modulant cytokines are administrated both as a mixture of recombinant proteins, peptides or fusion proteins (Tat/Nef, Tat/Rev, Tat/Gag, Tat/IL-12, Tat/IL-15) or as plasmid DNA.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: June 12, 2012
    Assignee: Istituto Superiore di Sanità
    Inventor: Barbara Ensoli
  • Patent number: 8182820
    Abstract: The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: May 22, 2012
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Janet K. Yamamoto, Jennifer White Janelle, Barbara Aurea Torres, Maki Arai, Taishi Tanabe, Ruiyu Pu
  • Patent number: 8173137
    Abstract: The present disclosure relates to vectors comprising polynucleotide sequences that encode HIV polypeptides. In particular, the disclosure relates polycistronic vector constructs comprising sequences that encode HIV polypeptides as a single polyprotein. Compositions comprising these vectors and sequences along with methods of using these vectors and sequences are also disclosed.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: May 8, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Jan Zur Megede, Susan W. Barnett
  • Patent number: 8168772
    Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: May 1, 2012
    Assignee: Altravax, Inc.
    Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
  • Patent number: 8168194
    Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.
    Type: Grant
    Filed: February 3, 2006
    Date of Patent: May 1, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Susan Barnett, Rino Rappuoli, Victoria A. Sharma, Indresh K. Srivastava, Jan Zur Megede
  • Patent number: 8158131
    Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: April 17, 2012
    Assignee: AltraVax, Inc.
    Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
  • Patent number: 8158130
    Abstract: Enveloped virus vectors are described which comprise a cellular virus receptor protein and which are capable of fusing with a cell which comprises a viral envelope protein to which the cellular virus receptor protein is cognate. Enveloped virus vectors comprising a plurality of cellular virus receptor proteins are also described. Methods for making the enveloped virus vectors are described, as are methods of using the enveloped virus vectors. The invention further relates to a lipoparticle comprising a membrane spanning protein, and the lipoparticle can be attached to a sensor surface. The invention relates to methods of producing and using the lipoparticle to, inter alia, assess protein binding interactions.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: April 17, 2012
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Robert W Doms, Joseph Rucker, Trevor L Hoffman, Paul Bates, James A Hoxie, Michael J Endres, John Balliet, Dennis L Kolson